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Abstract
Cancer is a term used for a classification of diseases in which abnormal cells divide
without control and invade other tissues. Cancer cases have been at an all time high as
of 2020, with an estimated 1.7 million new cases in 2019 alone. Due to the severity and
lethality of this type of disease, many billions of dollars have been invested in finding
a cure, but one is yet to be obtained. A newer form of tumor therapy to help with
this disease is being researched, called oncolytic virus therapy. An oncolytic virus is
one which specifically targets cancerous cells using proteins expressed on the outside of
only infected cells. In this paper, we expand on a simple oncolytic virus therapy model
created by Wodarz to model an agent-based system where no spatial restrictions are
in place, infections are driven by laws of mass-action, and we assume a simple in-vitro
environment. We evaluate these models in an ideal environment with qualitative and
quantitative analysis, and compare the result to the results found by Wodarz in the
in-vitro simulations he performed. We conclude with an evaluation of when the model
is effective for the simulation of a spatially sensitive system, and attempt to explain
the mathematical complexities with those cases where it’s ineffective.
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1 Biological Background
Cancer, or malignancy, is an abstract term collecting all diseases which display an ab-
normal growth of cells. In every type of cancer, some of the body’s cells begin to divide
without stopping and spread into the surrounding tissues. In the body, cells typically grow
and divide to form new cells when the body needs them to replace damaged or dead cells.
Cancerous cells may survive when they should die, and begin to form new cells when they’re
not needed. These cells may divide further without need and form growths on the body
called tumors.
Most cancer types are genetic diseases caused by mutations within certain genes which
often allow cells to ignore signals which regulate cell growth and apoptosis. The three
main types of genes which contribute to cancer growth when modified would be the proto-
oncogenes, tumor suppressor genes, and DNA repair genes. Proto-oncogenes are the normal
cell growth and division genes which become more active when a cancer causing mutation
exists. Tumor suppressor genes are genes which contribute to the regulation of cell growth
when excess division occurs. DNA repair genes are genes responsible for fixing damaged
DNA, and with the restriction of this gene’s expression comes the ability for more mutations
to occur[5].
When any combination of these three types of genes are mutated, cancer often ensues.
Along with the cancerous mutations, cells develop genetic impairments in their antiviral
defenses which make them susceptible to infection.
In this new form of immunotherapy, we take advatage of this susceptibility and engineer
viruses to target cancer cells. These engineered viruses, called oncolytic viruses, are modified
versions of viruses such as hepatitis B virus(HBV) or human papilloma virus(HPV) which
are intentionally designed to attack tumors which have already formed. Within these viruses
immune-stimulating genes are inserted and targets of the tumerous cells are removed.[1] The
oncolytic effect can take three distinct modes of virus-host interactions. One form would be
repeated cycles of virus replication in the tumor, where the virus replicates itself within the
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tumor and leads to cell death and tumor reduction. Another would be a low reproductive
rate with a highly cytotoxic protein being produced to damage the cell. The last form would
be virus infection of cancer cells which induce antitumor immunity. This infection causes
inflammation and lymphocyte penetration into the tumor, with the virus antigens eliciting
increased sensitivity to tumor necrosis factor-mediated killing.[6]
Figure 1: The Oncolytic Viruses invading normal cells and cancer cells[3]
Within this paper we will be discussing the differences between a virus which is highly
cytotoxic but slowly replicating, and one whcih is less cytotoxic and replicating faster. The
ultimate goal is to eradicate the non-infected cancerous cells within a tumor. When consid-
ering the best option between these two, we must also consider the effects of cancer on the
immune system as well as the dangers of introducing a new disease into the body in doses
large enough to kill a tumor or to replicate to become that large. Cancers often inhibit the
immune response in the body, weakening the immune system and making the host more
susceptible to new diseases. Therefore, introducing a new virus which the body is unfamiliar
with can cause dangerous side effects. This is why the viral cells should only be able to
replicate within the environment of the tumor cells, and spread only through the tumor.
This problem leads to another question, where should the virus be injected? When in-
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jected into the bloodstream, the virus will run into various barrier provided by the weakened,
but still functioning, immune system.
Figure 2: Visualization of the liver interacting with an oncolytic virus when injected into
the bloodstream[3]
It can be seen that the liver and the spleen can sequester a large amount of the virus
dosage and remove it from the body through natural excretion methods, significantly reduc-
ing the amount of the dosage which is applied to the cancerous cells they are meant for. Some
viruses have been clinically proven to evade antibodies, while others may remain infectious
to the target cells while being bound to antibodies. Others may be engineered to infect cells
of the immune system and be transferred by the bloodstream to the cancerous cells. The
most promising mode of delivery, however, is the use of cell carriers. This is the case because
they provide protection from the immune system, passing through it undetected.[3]
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2 The Model
Many mathematical models have been created around this subject, specifically attempt-
ing to analyze the efficiency by which the oncolytic viruses target the cancerous cells. In a
paper by Wu, Kirn, and Wein[9], the model presented takes into account the immune re-
sponse to the administered virus by introducing the tumor as a mass of constantly distributed
liquid particles wherein the cells move by convection with a velocity function dependent on
the radial distance from the center and the time from the beginning of simulation.
We begin our modeling with a simple ordinary differential equations model described by
Wodarz [8] which is derived from the agent based model which expresses all infection and
reproduction events driven by the Law of Mass Action:
dS(t)
dt
= rS(t)
(
1− S(t) + I(t)
K
)
− βS(t)I(t)
K
dI(t)
dt
= βS(t)I(t)
K
− aI(t) (1)
Where the number of uninfected tumerous cells at time t is denoted by S(t), and the number
of infected cells at time t by I(t). K here is a carrying capacity, usually determined by the size
of the tumor and the number of cancerous cells within it. r represents the reproductive rate
of cancerous cells, limited to the carrying capacity of the system by
(
1− S(t)+I(t)
K
)
. β is the
infection rate due to interaction between S(t) and I(t). a is the death rate of the infected cells,
where the average lifespan of an infected cell is 1/a.This modified Lotka-Volterra system[7]
is a very well understood mathematical model with plenty of documentation regarding the
qualitative analysis, which we will return to later.
The model presented by Wozard can be used to describe a spatially sensitive environment
by developing a simulation in which uninfected cells and infected cells are allowed to expand
in space. Wozard ran 7 simulations, all of which began with the environment being a 300x300
grid of cells wherein a 5x5 block of cancerous infected cells are placed in the middle of a
13x13 block of uninfected cells. From this we gain our initial condition for the analysis of
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the model. That is:
S(0) = 169
U(0) = 25
K = 90000 (2)
Even though the spatial stochastic predator-prey system studied here shows many patterns,
the dynamics shown in all of them can be understood by studying the local interactions of the
agents. According to Pascual et. al., in a class of systems exhibiting oscillatory dynamics,
the functional forms governing the local predator-prey interactions at those characteristic
scales are the same as the ones describing a perfectly mixed, mass-action system. [8]
3 Analysis
In analysis of this system, we first use the method defined in the Castillo-Chavez Paper[2]
to determine the equilibria of which there are three:
(S0, I0) = (0, 0)
(S1, I1) = (K, 0)
(S2, I2) =
(
aK
β
,
rK (β − a)
β (r + β)
)
(3)
In the first equilibria, the populations are both extinct. We call this the trivial equilibrium
since it biologically implies that no susceptible cells exist. In the second equilibria, the
uninfected population persists at the carrying capacity and the virus population is extinct.
We call this the disease free equilibrium. The third equilibria demonstrates where the virus
successfully infects the tumor and spreads until an equilibrium is reached. We call this
an endemic equilibrium since the susceptible and infected classes both exist. This third
equilibrium is stable if a < β, and can be approached monotonically or involve a system of
dampened oscillations.
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Next, we use the method of linearization to reduce the system of non-linear ordinary
differential equations to a system of linear differential equations, in order to estimate the
solution of the equation for a given time value t. To do this, we first determine the fixed
points of our system. We know from the above analysis that the system has three fixed points
defined to be the equilibria. We will use this linearization to perform stability analysis as
described in [4]. Now let:
f1(~x(t)) = rS(t)
(
1− S(t) + I(t)
K
)
− βS(t)I(t)
K
f2(~x(t)) =
βS(t)I(t)
K
− aI(t) (4)
where
~x(t) =
S(t)
I(t)

represents the functions we look to approximate the numbers for. Let ~a1, ~a2, and ~a3 be the
three fixed points vectors. Then we set up the system:
~y(t) = ~x(t)− ~a (5)
Which by differentiation implies:
d ~y(t)
dt
= d
~x(t)
dt
=
f1(~x(t))
f2(~x(t))
 = ~f(x(t)) = ~f(x(t)) + ~f(a)
Since ~f(a)=0 by definition. Then we can approximate towards linearization:
d ~y(t)
dt
= ~f(x(t)) + ~f(a) ≈
(
d ~f(a)
)
(~x− ~a) = J~y
where J represents the Jacobian matrix of the above system evaluated at each of the fixed
points. For our model, the Jacobian matrix is
J( ~x(t)) =

rK−2rS(t)−(r+β)I(t)
K
(r−β)S(t)
K
βI(t)
K
βS(t)−aK
K

∣∣∣∣∣ ~x(t)=~a (6)
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The solution for this system is found to be
y(t) ≈
6∑
i=1
Cie
λit ~λi (7)
where λi and ~λi are the ith eigenvalue and eigenvector of the matrix J respectively. We will
look at each solution in the summation to predict the behavior of each. In our model, there
are three cases for ~a.
Case 1 ~a = ~a1. Then the J matrix becomes:
J =
r 0
0 −a

who has eigenvalues:
λ1 = r
λ2 = −a
and respective eigenvectors:
~λ1 = C1
1
0

~λ2 = C2
0
1

Since we assumed non-zero positive real values for the coefficients of the equations, we know
λ1 is positive and λ2 is negative. Regardless of the values of r and β, this fixed point will be
a saddle point.
Case 2 ~a = ~a2. Then the J matrix becomes:
J =
−r −(r + β)
0 r − a

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who has eigenvalues:
λ3 = −r
λ4 = r − a
and respective eigenvectors:
~λ3 = C3
1
0

~λ4 = C4
 r+βa+2r
1

By the same logic as above, we know λ3 is negative. Here, we have 3 cases for what the fixed
point will be classified as:
Subcase 1 : r < a. In this case, the second eigenvalue will also be negative. This would
result in the fixed point being a stable node.
Subcase 2 : r > a. In this case the second eigenvalue will be positive. This would result
in a saddle point as well.
Subcase 3 : r = a. In this case the second eigenvalue will be zero. There will be no
motion in regards to the second eigenvalue. Instead, it will run parallel to the first eigenvalue.
Case 3 ~a = ~a3. Then the J matrix becomes:
J =

r
(
K− 2Ka
β
−Kβr−Kar
β2+βr
)
−β(Kβr−Kar)
β2+βr
K
− (r+β)a
β
β(Kβr−Kar)
K(β2+βr)
rKa
β
−aK
K

who has eigenvalues:
λ5 =
−12aβ + 12
√
a2β2 + 4a2r2 − 4aβ2r
β
λ6 =
−12aβ − 12
√
a2β2 + 4a2r2 − 4aβ2r
β
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and respective eigenvectors:
~λ5 = C5

(r+β)a
− 12aβ+ 12
√
a2β2+4a2r2−4aβ2r+ra
1

~λ6 = C6
 1(r+β)a
− 12aβ− 12
√
a2β2+4a2r2−4aβ2r+ra

This pair of eigenvalues has a variety of classifications based on the values of a, β, and r.
Subcase 1 : a2β2 + 4a2r2 ≥ 4aβ2r This case implies the eigenvalues are both real
numbers. In this case, we know λ6 is always negative. If
√
a2β2 + 4a2r2 − 4aβ2r > aβ, then
λ5 is positive and the fixed point is a saddle point. If
√
a2β2 + 4a2r2 − 4aβ2r < aβ, then λ5
is negative and the fixed point is a stable node. If
√
a2β2 + 4a2r2 − 4aβ2r = aβ then λ5 is 0
and we have the same parallel motion as described above.
Subcase 2 : a2β2 + 4a2r2 < 4aβ2r. This case implies both eigenvalues are complex
numbers. In this case, we would have negative real parts in both so we have exponential
decay in a stable spiral.
Figure 3: The result of Wozard’s simulation [8]
This figure shows 4 snapshots in time in the agent based model with the parameters r, β,
and a being modified. The selected values for each simulation are given:
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Simulation r β a
Simulation A 0.013 0.14 0.003
Simulation A1 0.15 0.32 0.007
Simulation B 0.014 0.015 0.00056
Simulation B1 0.04 0.032 0.016
Simulation C 0.014 0.032 0.008
Simulation D 0.0002 0.019 0.0032
Simulation D1 0.069 0.64 0.18
We can see a variety of interaction types form. In A, we see an execution of a virus-
mediated target cell-extinction system. In this case, both the targeted cell and the virus is
spreading in space as a wave, but the virus infection ring overtakes the uninfected replication
ring, causing the uninfected cells to disappear. The virus is strong enough to eliminate the
wave. In A1, we see a modified version of A where the disease spreads similarly, but only
partially breaks up the cell wave. The structure allows uninfected cells to spread out in all
directions and cause new moving fronts. We call this Low level target cell persistence.
The coefficient values in A cause the disease free equilibrium to be a stable node and the
endemic equilibrium to be approached in a stable spiral. Due to the initial conditions, our
solution approached the endemic equilibrium. The coefficient values in A1 cause the disease
free equilibrium to be a saddle point, and the endemic equilibrium to be approached in a
stable spiral. We see similar behaviors expressed in the Wodarz simulation in Figure 4.
In B, we see a boundary mediated extinction scenario, where the infection and the growth
occur at almost the exact same rate. The rings spread but the virus never overtakes the
growth. This leads to cell extinction when the boundary is reached. Since it is possible
for real tumors to break out of the carrying capacity of their environment, the genetic
transformations needed to do so take place on a longer time scale, so it is reasonable to
assume some sort of geometric constraints. B1 expresses a concentric ring pattern tending
to target cell persistence at low levels. This is due to the existence of uninfected cells left
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behind by the expanding ring of virus cells. The existence here leads to new target cell
growth, followed by new virus growth, leading to new wave structures to form.
The coefficient values in B cause the disease free equilibrium to be a saddle point and
the endemic equilibrium to be approached in a stable spiral. Due to our initial conditions,
the simulation approaches the endemic equilibrium, unlike the natural simulation. The
coefficient values of B1 cause the disease free equilibrium to be a saddle point and the
endemic equilibrium to be approached in a stable spiral. Our initial conditions cause the
solution to approach the endemic equilibrium.
In C, we see a constant density coexistence between the virus and the uninfected cells. As
the virus spreads in space, many uninfected cells are left uninfected, leading to the dispersion
of the initial expansion and the lack of waves. This is the well mixed system which reaches
an equilibrium density after a finite amount of time.
The coefficient values in C cause the disease free equilibrium to be a saddle point and
the endemic equilibrium to be approached in the stable spiral. Our initial conditions make
the simulation approach the endemic equilibrium, which makes sense biologically.
In D, we see a virus extinction despite having invaded the population. The virus reduces
the cancer load by a small amount, and dies off in the process. The cancer is then left to
grow unopposed. This result is less likely to occur when the virus strength increases, which
is quantified by the ratio a/β. In D1, we see low-level virus persistence. While the virus
invades the target cell population, it also converges to its local equilibrium value.
The coefficient values of D cause the disease free equilibrium and the endemic equilibrium
to be stable nodes. Our initial conditions tend to the disease free equilibrium. The coefficients
in D1 cause the disease free equilibrium to be a stable node and the endemic equilibrium to
be approached in a stable spiral. Our initial conditions cause the simulation to tend towards
the endemic equilibrium.
Overall, we can see the model is effective in recreating the actual results for the 300x300
in-vitro experiment run by Wozard.
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4 Conclusions
The use of Oncolytic Viruses in Tumor Therapy can be a very powerful tool in the
study of immunotherapy. This review employed standard qualitative analysis techniques to
generalize the behavior, as well as standard quantitative analysis to demonstrate where the
model can successfully be used to demonstrate the natural long term behavior of the disease.
The use of ordinary differential equations is employed often in the field of virus dynamics
and yield many useful results. With these models comes weaknesses in the predictive power
in situations such as these. In reality, it’s almost impossible to exactly predict the natural
world due to the random behavior exhibited in nature. These models also are in-effective in
exactly describing an in-vivo environment for the same reason. Even with these weaknesses,
ordinary differential equation models can be powerful in describing ideal behaviors of these
environments.
Other research done with these models include validating these models with scientific
experiments as done by Wodarz, and introducing additional biological complexities with
the goal of creating a biologically realistic model which can be used to develop treatment
strategies for diseases which previously had no cure in sight.
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5 Figures
Figure 4: The result of maple simulation using simulation A values
Figure 5: The result of maple simulation using simulation A1 values
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Figure 6: The result of maple simulation using simulation B values compared to an experi-
ment run by Wodarz
Figure 7: The result of maple simulation using simulation B1 values compared to an exper-
iment run by Wodarz
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Figure 8: The result of maple simulation using simulation C values compared to an experi-
ment run by Wodarz
Figure 9: The result of maple simulation using simulation D values compared to an experi-
ment run by Wodarz
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Figure 10: The result of maple simulation using simulation D1 values compared to an in-vitro
experiment run by Wodarz
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